[HTML][HTML] Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
P Ge, N Wan, X Han, X Wang, J Zhang… - Frontiers in …, 2022 - frontiersin.org
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
P Ge, N Wan, X Han, X Wang… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.
P Ge, N Wan, X Han, X Wang, J Zhang… - Frontiers in …, 2022 - europepmc.org
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
[HTML][HTML] Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
P Ge, N Wan, X Han, X Wang, J Zhang… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
P Ge, N Wan, X Han, X Wang, J Zhang, X Long… - 2022 - repository.um.edu.mo
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.
P Ge, N Wan, X Han, X Wang, J Zhang… - Frontiers in …, 2022 - europepmc.org
Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …